← Back to Search

Procedure

Phaco/Trabectome vs. Phaco/Kahook for Glaucoma

N/A

Waitlist Available

Led By Asher Weiner, MD

Research Sponsored by State University of New York at Buffalo

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial will compare the Kahook dual blade to Trabectome in lowering IOP in glaucoma patients during cataract surgery. The investigators hope to show that the Kahook dual blade is just as effective and safe as Trabectome.

Who is the study for?

This trial is for adults over 18 with various types of open-angle glaucoma and visually-significant cataract in both eyes, who need to lower their eye pressure or reduce glaucoma medication. It's not for those under 18, unwilling to consent, with previous failed eye surgeries, closed angle glaucoma, or women who can become pregnant.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of two surgical methods: Kahook Dual Blade (KDB) versus Trabectome when combined with cataract surgery (Phacoemulsification) in reducing intraocular pressure in patients with glaucoma.See study design

What are the potential side effects?

Possible side effects include hyphema (blood in the front area of the eye), similar complications as other minor invasive glaucoma surgeries (MIGS), and typical risks associated with cataract surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Body Weight Changes

Secondary outcome measures

Changes in number of medications between baseline and postoperative followup visits

Changes in visual acuity measurements measured using a Snellen Vision Chart between baseline and postoperative followup visits

Rate of post surgical complications

Trial Design

2Treatment groups

Active Control

Group I: Phaco/KDBActive Control1 Intervention

Eyes needing glaucoma and cataract extraction will receive combined KDB and phacoemulsification in one eye of a patient

Group II: Phaco/TrabectomeActive Control1 Intervention

Contralateral eyes needing glaucoma and cataract extraction will receive combined Trabectome and phacoemulsification in contralateral eye of the same patient

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

State University of New York at BuffaloLead Sponsor

246 Previous Clinical Trials

49,408 Total Patients Enrolled

3 Trials studying Glaucoma

376 Patients Enrolled for Glaucoma

Asher Weiner, MD4.612 ReviewsPrincipal Investigator - State University of New York at Buffalo

State University of New York at Buffalo

1 Previous Clinical Trials

70 Total Patients Enrolled

1 Trials studying Glaucoma

70 Patients Enrolled for Glaucoma

5Patient Review

This physician is not only competent, but they also genuinely care about their patients.

Media Library

KDB/Phacoemulsification (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03894631 — N/A

Glaucoma Research Study Groups: Phaco/KDB, Phaco/Trabectome

Glaucoma Clinical Trial 2023: KDB/Phacoemulsification Highlights & Side Effects. Trial Name: NCT03894631 — N/A

KDB/Phacoemulsification (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03894631 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical trial allow for the participation of individuals under 25 years old?

"The enrollment pool for this clinical trial is limited to those between the ages of 18 and 95. However, there are 23 trials that can accommodate minors and 191 studies dedicated to seniors."

Answered by AI

Who is eligible to enlist in this experiment?

"This clinical trial seeks eighty individuals aged 18 to 95 who suffer from glaucoma. To be eligible, patients must have one of the following conditions: Primary open angle glaucoma (POAG), Low-tension glaucoma (LTG), Pseudoexfoliation glaucoma (PSXF), pigmentary glaucoma and other structurally normal looking forms of open angle in both eyes. As well, they need to already be diagnosed with Glaucoma and Cataract in both eyes; possess a visually-significant cataract in both eyes; require reduction or replacement of their"

Answered by AI

Are there currently any open slots for participation in this experiment?

"According to data hosted on clinicaltrials.gov, this study is not currently accepting applicants. Initially posted on the 6th of March 2019 and last updated on October 26th 2022, it appears that recruitment for this medical trial has ended; however, there are 206 other active trials seeking participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Effect of Intra-subject Phaco/Trabectome vs. Phaco/Kahook Dual Blade on Intraocular Pressure

Asher Weiner, MD 2019. "Effect of Intra-subject Phaco/Trabectome vs. Phaco/Kahook Dual Blade on Intraocular Pressure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03894631.

All > Intraocular Lens